Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingavirin in mild COVID-19
NCT05216497Phase 3Completed
- Sponsor
- Valenta Pharm
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ingavirin with Placebo (2 arms). Primary endpoint: Time to clinical recovery. Started Oct 2021; status: completed.
02
Drugs
Ingavirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05216497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216497.